Blog

Forward by Rick Gurz: I am excited to bring in a guest author today, Dr. Nash Rochman. He is a research fellow at the National Institutes of Health. Dr. Rochman will discuss how a few novel approaches targeting diverse aspects of Alzheimer’s disease onset and progression are likely to dramatically alter the landscape of treatment for neurodegenerative diseases.  

Every year, Forbes scours the nation for wealth advisors that are a cut above the rest for their best-in-state rankings. This year we are proud to announce that Rick Gurz has received this important accolade! While it’s no surprise to us, it’s an honor to be recognized for the work that Quantis Wealth Management does for our clients and our community. 

The past few months have demonstrated that mRNA vaccines can be highly effective, economically viable, and rapidly developed. It’s easy to imagine future applications where mRNA vaccines will become the standard approach and displace traditional technologies. 

At the heart of these successes lies advances in drug delivery, which may continue to provide momentum for not only the expanding repertoire of mRNA therapeutics, but a broad array of gene editing technologies (like CRISPR) as well. The exciting news last week from Intellia Therapeutics, is no exception.